Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...7891011121314151617...208209»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Focus V (anlotinib) / Advenchen
    Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (Pubmed Central) -  Mar 7, 2026   
    Moreover, the radiomics nomogram is a valuable tool for refining patient selection and advancing personalized treatment strategies for individuals with uHCC. The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
  • ||||||||||  zeprumetostat (SHR-2554) / Treeline Biosci
    Journal:  Zeprumetostat: First Approval. (Pubmed Central) -  Mar 7, 2026   
    1 line of systemic therapy. This article summarizes the milestones in the development of zeprumetostat leading to this first approval for the treatment of r/r PTCL.
  • ||||||||||  Retrospective data, Journal, HEOR:  Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis. (Pubmed Central) -  Mar 7, 2026   
    Codrituzumab 1600?mg administered every 2 weeks demonstrated the most advantageous health profile, markedly decreasing AEs and instances of grade 3-4 AEs...Cabozantinib 60?mg QD and pembrolizumab 200?mg Q3W arise as the most suitable second-line therapies alternatives for advanced HCC, offering substantial improvements in survival and disease control with manageable adverse effects. These findings support the integration of both targeted and immune therapies in handling of advanced HCC.
  • ||||||||||  Journal:  Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy. (Pubmed Central) -  Mar 7, 2026   
    Furthermore, probable challenges in PARPi application and drug resistance mechanisms have also been discussed. Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Recent highlights and breakthroughs in immunotherapy for head and neck cancers. (Pubmed Central) -  Mar 6, 2026   
    Lipo-IRI may be a good option as a component of standard second-line for patients with relapsed/metastatic colorectal cancer. Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.
  • ||||||||||  oxaliplatin / Generic mfg., Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  Subacute liver failure caused by immunotherapy in a patient with gastric cancer was improved after multimodal treatment with artificial liver combined with liver-protective drugs: a case report. (Pubmed Central) -  Mar 6, 2026   
    This report describes a rare case of severe immune-mediated hepatotoxicity (IMH) in a 76-year-old male patient with postoperative gastric cancer who was undergoing adjuvant therapy with camrelizumab in combination with oxaliplatin and S-1 (SOX regimen)...No tumor recurrence occurred during follow-up, and hepatic function remained stable through August 2025. This case highlights the critical need for early recognition and prompt, comprehensive management of severe ICI-related liver injury and supports the potential clinical utility of artificial liver support systems in such scenarios.
  • ||||||||||  FROM FEASIBILITY TO FINDINGS: SUPPORTING INDIRECT TREATMENT COMPARISONS WITH GENERATIVE AI () -  Mar 6, 2026 - Abstract #ISPOR2026ISPOR_1397;    
    Bayesian NMA results showed significant overall survival benefits for sintilimab plus bevacizumab (HR 0.38; 95% CrI 0.21-0.79), camrelizumab plus rivoceranib (HR 0.42; 0.21-0.82), and atezolizumab plus bevacizumab (HR 0.45; 0.23-0.87) compared with placebo. GenAI can streamline ITC workflows by supporting feasibility assessment, analysis planning, and result interpretation, and when combined with standard NMA tools and expert review enhances efficiency while preserving rigor and enabling faster evidence generation for HTA and JCA use cases.
  • ||||||||||  Do SGLT2 Inhibitors Influence Parkinson's Disease Risk? A Meta-analysis of Randomized Trials (McCormick Place West | Hall F; In-Person; Virtual) -  Mar 5, 2026 - Abstract #AAN2026AAN_4436;    
    Building on its efficacy advantages, trastuzumab rezetecan offers a novel therapeutic option for HER2-mutant NSCLC patients, thereby enhancing their overall health outcomes. No eligible data were found for ertugliflozin, enavogliflozin, henagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin...Subgroup analyses showed no significant effect for individual agents: empagliflozin 10 mg (OR 0.64, 95% CI 0.17
  • ||||||||||  SHR-1819 / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change:  A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) -  Mar 5, 2026   
    P2,  N=79, Completed, 
    No eligible data were found for ertugliflozin, enavogliflozin, henagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin...Subgroup analyses showed no significant effect for individual agents: empagliflozin 10 mg (OR 0.64, 95% CI 0.17 Enrolling by invitation --> Completed | N=240 --> 79
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (clinicaltrials.gov) -  Mar 4, 2026   
    P=N/A,  N=153, Completed, 
    The combination of adebrelimab, bevacizumab, and cisplatin/carboplatin was the first regimen to demonstrate promising intracranial antitumor activity and prolonged PFS and CNS-PFS, along with a manageable safety profile, warranting further investigation. Recruiting --> Completed | Trial completion date: Jan 2028 --> Jul 2025 | Trial primary completion date: Jun 2026 --> Jul 2025
  • ||||||||||  zeprumetostat (SHR-2554) / Treeline Biosci, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
    Enrollment open:  A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov) -  Mar 3, 2026   
    P2,  N=218, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / Elevar Therapeutics
    A Unique Case of Multiple Primary Lung Cancer With Three Distinct Histological Tumor Subtypes and Different Gene Mutations (W314 (Level III, OCCC West Concourse); Poster Board # 720) -  Mar 3, 2026 - Abstract #ATS2026ATS_8520;    
    Patient received four cycles of postoperative adjuvant chemotherapy [Docetaxel + Nedaplatin]...Six cycles of adjuvant chemotherapy [Etoposide+ Nedaplatin] and five cycles of immunotherapy [Camrelizumab] were administered postoperatively...Genetic results reveal completely different origins, and potentially treatment options for various lesions. Smoking is a risk factor for MPLC, but additional mechanistic research is required.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Adebrelimab plus chemotherapy for extensive-stage small-cell lung cancer: A real-world study (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2071;    
    For safety analysis, one patient experienced grade 3 intestinal obstruction, and two patients experienced grade 2 hepatic dysfunction. [Conclusions] In real-world settings, adebrelimab combined with chemotherapy showed promising efficacy and acceptable safety for treating ES-SCLC.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Adebrelimab plus chemotherapy as first-line treatment for ES-SCLC: A real-world retrospective study (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2066;    
    The most common adverse event was myelosuppression, observed in 12 patients (63.2%) of any grade, including grade ?3 in 3 patients (15.8%). [Conclusions] In real-world settings, adebrelimab combined with chemotherapy demonstrated encouraging efficacy and acceptable safety as a first-line treatment for ES-SCLC.
  • ||||||||||  First-Line Treatment Recommended by the Chinese National Guidelines for Primary Liver Cancer: A Network Meta-Analysis (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2050;    
    Compared to sorafenib, atezolizumab + bevacizumab, camrelizumab + apatinib, and donafenib significantly reduced mortality additionally, compared to lenvatinib, both atezolizumab + bevacizumab and camrelizumab + apatinib demonstrated survival benefit. [Conclusions] Camrelizumab + apatinib may offer the most favorable PFS and OS among first-line therapies currently recommended in the Chinese guidelines for liver cancer.
  • ||||||||||  First-Line Systemic Therapies for Hepatocellular Carcinoma with MVI and EHS: A Network Meta-Analysis (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2040;    
    The top three ranked treatment regimens for overall survival benefit were Camrelizumab plus apatinib (41.3%), Sintilimab plus bevacizumab biosimilar (36.3%), and Atezolizumab plus bevacizumab (19.1%). [Conclusions] For HCC with MVI and EHS, Camrelizumab plus apatinib may be considered the preferred first-line treatment option.
  • ||||||||||  AiRuiKa (camrelizumab) / Elevar Therapeutics
    Camrelizumab plus chemotherapy achieved long-term survival in advanced non-small cell lung cancer: A case series (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2023;    
    Treatment switched to camrelizumab, albumin-bound paclitaxel, and carboplatin for five cycles, followed by 37 cycles of camrelizumab plus anlotinib...Case 4 A patient with lung adenocarcinoma started camrelizumab, pemetrexed, and carboplatin in February 2023, followed by maintenance with pemetrexed plus camrelizumab...Conclusions Camrelizumab plus chemotherapy yielded long-term survival in some advanced NSCLC patients in real-world practice. Further studies are needed to elucidate the mechanisms driving these responses.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / Elevar Therapeutics
    Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Squamous NSCLC: A Network Meta-Analysis (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_2018;    
    probabilities of OS benefit from sintilimab plus chemotherapy and camrelizumab plus chemotherapy as first-line treatments for sqNSCLC were similar. [Conclusions] Considering the PFS and OS benefits of camrelizumab plus chemotherapy as first-line treatment for sqNSCLC, it may be regarded as a preferred therapeutic option.